Treatment - Page 7 of 471 Posts on Medivizor
Navigation Menu

Treatment Posts on Medivizor

Evaluating the risk of cardiovascular side effects in cancer patients treated with PD-1/PD-L1 inhibitors.

Evaluating the risk of cardiovascular side effects in cancer patients treated with PD-1/PD-L1 inhibitors.

Posted by on Apr 30, 2023 in Melanoma | 0 comments

In a nutshell This study evaluated the risk of cardiovascular (CV; heart and blood vessels) side effects in cancer patients treated with PD-1/PD-L1 inhibitors. The data showed that PD-1/PD-L1 inhibitors alone or combined with chemotherapy significantly increased the risk of CV side effects. PD-1/PD-L1 inhibitors combined with chemotherapy significantly...

Read More

Evaluating the effects of split-belt treadmill versus tied-belt treadmill training on gait adaptation in patients with Parkinson’s disease.

Evaluating the effects of split-belt treadmill versus tied-belt treadmill training on gait adaptation in patients with Parkinson’s disease.

Posted by on Apr 30, 2023 in Parkinson's Disease | 0 comments

In a nutshell This study evaluated the effects of split-belt treadmill (SBT) versus tied-belt treadmill (TBT) training on gait adaptation in patients with Parkinson’s disease (PD). The data showed that SBT training significantly improved gait adaptation compared to TBT in these patients.  Some background PD is a disorder in which part of...

Read More

Evaluating the effectiveness and safety of adding isatuximab to lenalidomide, bortezomib, and dexamethasone combination for patients with newly diagnosed transplantation-eligible multiple myeloma.

Evaluating the effectiveness and safety of adding isatuximab to lenalidomide, bortezomib, and dexamethasone combination for patients with newly diagnosed transplantation-eligible multiple myeloma.

Posted by on Apr 30, 2023 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of adding isatuximab (Sarclisa) to lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (Decadron) combination as induction therapy for patients with newly diagnosed transplantation-eligible multiple myeloma (MM). The data showed that the addition of isatuximab to lenalidomide,...

Read More

Evaluating the effectiveness and safety of a tumor bed boost after whole breast irradiation following breast-conserving surgery in patients with non-low-risk ductal carcinoma in situ.

Evaluating the effectiveness and safety of a tumor bed boost after whole breast irradiation following breast-conserving surgery in patients with non-low-risk ductal carcinoma in situ.

Posted by on Apr 23, 2023 in Breast cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of a tumor bed (where the tumor was present) boost after whole breast irradiation (WBI) following breast-conserving surgery (BCS) in patients with non-low-risk ductal carcinoma in situ (DCIS). The data showed that a tumor bed boost after WBI following BCS reduced local recurrence (return...

Read More

Evaluating the long-term outcomes of catheter-based renal artery denervation in patients with uncontrolled hypertension.

Evaluating the long-term outcomes of catheter-based renal artery denervation in patients with uncontrolled hypertension.

Posted by on Apr 23, 2023 in Hypertension | 0 comments

In a nutshell This study reported the long-term outcomes of catheter-based renal artery denervation (CB-RD) in patients with resistant or uncontrolled hypertension [high blood pressure (BP)]. The data showed that over the long-term CB-RD was safe and had significantly greater reductions in BP and better BP control compared with a sham control in these...

Read More

Evaluating the effectiveness and safety of asciminib in real-world patients with chronic myeloid leukemia previously treated with ponatinib.

Evaluating the effectiveness and safety of asciminib in real-world patients with chronic myeloid leukemia previously treated with ponatinib.

Posted by on Apr 23, 2023 in Leukemia | 0 comments

In a nutshell This study evaluated the effectiveness and safety of asciminib (Scemblix) in real-world patients with chronic myeloid leukemia (CML) previously treated with ponatinib (Iclusig). The data showed that asciminib treatment had promising effectiveness in these patients. Some background CML is a type of cancer that starts in blood-forming...

Read More

Evaluating the effectiveness of degarelix with or without apalutamide before prostate surgery in patients with high-risk prostate cancer.

Evaluating the effectiveness of degarelix with or without apalutamide before prostate surgery in patients with high-risk prostate cancer.

Posted by on Apr 23, 2023 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness of degarelix (Firmagon) with or without apalutamide (Erleada) before radical prostatectomy (RP; prostate surgery) in patients with high-risk prostate cancer (PC). The data showed that degarelix plus apalutamide significantly improved the pathological response in these patients. Some background...

Read More

Evaluating whether there is an association between fertility treatments and the risk of breast cancer in women with a family history of breast cancer or with BRCA mutations.

Evaluating whether there is an association between fertility treatments and the risk of breast cancer in women with a family history of breast cancer or with BRCA mutations.

Posted by on Apr 23, 2023 in Infertility | 0 comments

In a nutshell This study evaluated whether fertility treatments increase the risk of breast cancer (BC) in women with a family history of BC or with BRCA mutations. The data showed that fertility treatments did not significantly increase the risk of BC in these women. Some background Treatment for infertility has become common, as people delay...

Read More

Evaluating the effectiveness and safety of sacituzumab govitecan versus chemotherapy in patients with HR+, HER2– metastatic breast cancer.

Evaluating the effectiveness and safety of sacituzumab govitecan versus chemotherapy in patients with HR+, HER2– metastatic breast cancer.

Posted by on Apr 23, 2023 in Breast cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of sacituzumab govitecan (Trodelvy; SG) compared to chemotherapy in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer (BC). The data showed that SG significantly improved survival without cancer progression compared to chemotherapy in these...

Read More

Evaluating the safety and effectiveness of nivolumab and relatlimab before surgery in patients with resectable melanoma

Evaluating the safety and effectiveness of nivolumab and relatlimab before surgery in patients with resectable melanoma

Posted by on Apr 15, 2023 in Melanoma | 0 comments

In a nutshell The study evaluated the safety and effectiveness of relatlimab (Opdualag) and nivolumab (Opdivo) combination therapy before surgery in patients with stages III and IV resectable melanoma. The study concluded that the relatlimab and nivolumab combination was safe and effective in these patients. Some background...

Read More

Can BCT-100 be safely combined with low-dose cytarabine for older patients with acute myeloid leukemia that cannot receive intensive therapy?

Can BCT-100 be safely combined with low-dose cytarabine for older patients with acute myeloid leukemia that cannot receive intensive therapy?

Posted by on Apr 15, 2023 in Leukemia | 0 comments

In a nutshell This study compared the effectiveness and safety of low-dose (LD) cytarabine (Ara-C; Cytosar-U) with recombinant arginase BCT-100 (BCT-100) to Ara-C alone in older patients with acute myeloid leukemia (AML) that were unsuitable for intensive therapy. The data showed that LD Ara-C (LDAC) combined with BCT-100 resulted in similar...

Read More